This observational study is designed to assess the long-term efficacy and safety of Epiduo (alone or in combination with other drugs) under daily clinical practice conditions in patients with moderate to severe inflammatory acne. In addition, the effect of Epiduo on quality of life and patient adherence will be assessed under marketed conditions.
This observational study is designed to assess the long-term efficacy and safety of Epiduo under daily clinical practice conditions. The study includes patients of all ages with moderate to severe inflammatory acne, taking Epiduo alone or in combination with other drugs. In addition, the effect of Epiduo alone or in combination with other drugs on quality of life and patient adherence will be assessed under marketed conditions. The observational study is designed as a multicentre study, covering all parts of Germany. Participating investigators are dermatologists with an adequate patient pool of acne patients. The observation time per patient will be 9 months. An interim and final examination with subsequent documentation are designated to be performed about 3 and 9 months after the start of treatment, respectively.
Study Type
OBSERVATIONAL
Enrollment
6,036
topical application
Severity of acne
Efficacy is assessed by change in severity of acne according to the Leeds revised grading system
Time frame: at baseline and after 3 and 9 months treatment
Quality of Life
Quality of life is assessed using the Cardiff Acne Disability Index
Time frame: at baseline and after 3 and 9 months of treatment
Treatment adherence
Treatment adherence is assessed by the physician using a mini-questionnaire published by the international acne expert group "Global Alliance to Improve Outcomes in Acne"
Time frame: after 3 and 9 months of treatment
Local Skin Irritations
Time frame: over 9 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.